Drug intelligence / Profile preview

bms-986251

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-986251 is a potent and selective small molecule inverse agonist of the retinoic acid-related orphan receptor gamma t (RORγt), developed by Bristol Myers Squibb for the treatment of inflammatory diseases such as psoriasis. The drug acts by inhibiting RORγt activity and thereby suppressing IL‑17 production—a key cytokine in Th17-mediated immune responses implicated in autoimmune conditions. BMS‑986251 demonstrated robust efficacy in preclinical models of skin inflammation and was orally bioavailable. Clinical development was discontinued after early-phase trials due to safety concerns[2][6][8][3].

Other names: (1R,3S,4R)-4-((3AR,9BR)-9B-((4-fluorophenyl)sulfonyl)-7-(perfluoropropan-2-yl)-2,3,3A,4,5,9B-hexahydro-1H-benzo(e)indole-3-carbonyl)-3-methylcyclohexane-1-carboxylic acid

Targets

RORγt

Beyond the preview

Go deeper on bms-986251.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bms-986251.

Explore the full profile